Furan-Triazole Derivatives: Synthesis and Antidiabetic Activity Data

Ten novel furan-clubbed 1,2,3-triazole derivatives were synthesized and evaluated as α-glucosidase inhibitors for diabetes management. The dataset, authored by Priya Devi and last updated in April 2026, includes in vitro inhibition results, in vivo mouse model data, and molecular docking analyses. Compound PD-10 exhibited the strongest inhibition with an IC50 of 13.82 μM, outperforming the standard drug acarbose.

Use Cases

• Training QSAR models based on synthesized compound structures and their IC50 values.
• Validating molecular docking protocols using the provided binding affinity scores (-4.34 kcal/mol for PD-10).
• Benchmarking new α-glucosidase inhibitors against the reported in vitro and in vivo efficacy data.
• Analyzing structure-activity relationships for furan-triazole derivatives from the ten synthesized compounds.

Strengths

• Includes multi-faceted validation data: in vitro enzyme inhibition, in vivo mouse model results, and molecular docking.
• Provides a direct performance benchmark against the standard drug acarbose (IC50 = 32.03 μM).
• Characterization data for all ten compounds is available via FT-IR, NMR, and LC-MS techniques.

Limitations

• The dataset is a single 8.9 MB DOCX file; column-level documentation and sample data are unavailable.
• Row count and tabular structure are unknown, requiring manual inspection after download.
• The primary data is embedded in a text document, which may complicate direct computational analysis.

Provenance

Source

figshare, authored by Priya Devi.

Collection Method

Experimental synthesis and characterization of ten novel compounds, followed by in vitro, in vivo, and computational evaluation.

Time Range

The study period is not specified, but the dataset was updated in April 2026.

Freshness

Last updated 2026-04-17 09:29:29

Geography

Spatial coverage is not specified.